论文部分内容阅读
目的探究顺铂和多西他赛联合放疗用于晚期肺癌的临床疗效。方法 50例接受放疗治疗的晚期肺癌患者,按照联合使用的药物不同分为研究组和对照组,各25例。研究组患者联合使用顺铂和多西他赛进行治疗,对照组联合使用顺铂和丝裂霉素进行治疗。比较两组患者的临床疗效。结果研究组总有效率为68.00%(17/25),对照组总有效率为36.00%(9/25),研究组治疗总有效率高于对照组,差异有统计学意义(χ~2=5.13,P=0.02<0.05);研究组患者在血小板、白细胞减少及恶心呕吐的发生率明显低于对照组,差异均有统计学意义(P<0.05);肝功能和肾功能损伤比较差异无统计学意义(P>0.05)。结论相较于丝裂霉素,多西他赛和顺铂联用更适合用于晚期肺癌的放疗治疗,值得临床推广应用。
Objective To investigate the clinical efficacy of combination of cisplatin and docetaxel in the treatment of advanced lung cancer. Methods Fifty patients with advanced lung cancer receiving radiotherapy were divided into study group and control group according to the different drugs used in combination, with 25 cases in each. Patients in the study group were treated with cisplatin and docetaxel, while those in the control group were treated with cisplatin and mitomycin. The clinical efficacy of the two groups was compared. Results The total effective rate was 68.00% (17/25) in the study group and 36.00% (9/25) in the control group. The total effective rate of the study group was higher than that of the control group (χ ~ 2 = 5.13, P = 0.02 <0.05). The incidence of thrombocytopenia, neutropenia and nausea and vomiting in the study group was significantly lower than that in the control group (P <0.05). There was no significant difference in the liver function and renal function between the two groups Statistical significance (P> 0.05). Conclusion Compared with mitomycin, docetaxel and cisplatin is more suitable for the treatment of advanced lung cancer radiotherapy, worthy of clinical application.